These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 8137251)

  • 1. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
    Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
    Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.
    Perez-Soler R; Ling YH; Zou Y; Priebe W
    Cancer Chemother Pharmacol; 1994; 34(2):109-18. PubMed ID: 8194162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles.
    Zou Y; Priebe W; Ling YH; Perez-Soler R
    Cancer Chemother Pharmacol; 1993; 32(3):190-6. PubMed ID: 8500223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.
    Zou Y; Priebe W; Stephens LC; Perez-Soler R
    Clin Cancer Res; 1995 Nov; 1(11):1369-74. PubMed ID: 9815933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
    Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline antibiotics with high liposome entrapment: structural features and biological activity.
    Perez-Soler R; Priebe W
    Cancer Res; 1990 Jul; 50(14):4260-6. PubMed ID: 2194651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
    Perez-Soler R; Neamati N; Zou Y; Schneider E; Doyle LA; Andreeff M; Priebe W; Ling YH
    Int J Cancer; 1997 Mar; 71(1):35-41. PubMed ID: 9096663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
    Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
    Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes.
    Zou Y; Ling YH; Reddy S; Priebe W; Perez-Soler R
    Int J Cancer; 1995 May; 61(5):666-71. PubMed ID: 7768640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model.
    Pan XQ; Wang H; Lee RJ
    Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
    Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
    Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R; Mayer LD
    Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of adriamycin against a liver metastatic model by encapsulation in liposomes.
    Yachi K; Suzuki N; Tanaka N; Okada K; Mitsui I; Kawato Y; Komagata Y; Komiyama K; Kikuchi H
    Biopharm Drug Dispos; 1996 Nov; 17(8):699-715. PubMed ID: 8950048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
    Ling YH; Priebe W; Yang LY; Burke TG; Pommier Y; Perez-Soler R
    Cancer Res; 1993 Apr; 53(7):1583-9. PubMed ID: 8453627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
    Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
    Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.
    Jin J; Sun H; Wei H; Liu G
    Invest New Drugs; 2007 Apr; 25(2):95-105. PubMed ID: 16937080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.